Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - phenobarbital - oral tablet - 30mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - phenobarbital sodium - solution for injection - 60mg/1ml

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - phenobarbital sodium - solution for injection - 60mg/1ml

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - phenobarbital - oral capsule - 60mg

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - phenobarbital - oral tablet - 60mg

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

proficient rx lp - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 32.4 mg - phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. controlled substance – phenobarbital is a schedule iv drug. dependence – barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - phenobarbital - oral tablet - 30mg

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

e5 pharma, llc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 16.2 mg - - sedative - anticonvulsant – for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. phenobarbital is a schedule iv drug. barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fata

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

sterling-knight pharmaceuticals, llc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 97.2 mg - a. sedative b. anticonvulsant – for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. controlled substance – phenobarbital is a schedule iv drug. dependence – barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the sam

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

contract pharmacy services-pa - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 32.4 mg - - sedative - anticonvulsant – for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. controlled substance – phenobarbital is a schedule iv drug. dependence – barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intox